Most importantly, IgE-targeted therapies may offer novel treatment strategies for distinct subgroups of lung cancer patients such as elderly subjects with high IgE levels, a history of smoking, low LMR values, and lymphocyte immunodeficiency. This evidence concerns the gene IGHE and lung carcinoma.